Investigación

Publicaciones Científicas

 

Uno de los principales fines de la Fundación es el de capacitar a profesionales y estimular la investigación científica, ahondando las causas y buscando nuevas formas y/o métodos en el tratamiento de enfermedades oncológicas, con el fin de reducir la incidencia de la enfermedad y encontrar su cura.

Para ello, en el Área de Investigación se llevan a cabo los estudios epidemiológicos, pre clínicos y clínicos, lo cual nos permite un mejor conocimiento para el tratamiento y el desarrollo de nuevas drogas.

 

PUBLICACIONES

 

2022 ASCO ANNUAL MEETING


-Update to role of the neutrophil lymphocyte ratio in patients with advanced NSCLC undergoing immunotherapy.


2021 ANNUAL MEETING


-Analysis of the relationship between different prognosis factors in patients with advanced colon cancer and progression-free survival.
    J Clin Oncol 39, 2021 (suppl 15; abstr e15518)

-Neutrophil-lymphocyte radio (NLR) as a possible predictive factor in patients with advanced NSCLC WHO received immunotherapy.
    J Clin Oncol 39, 2021 (suppl 15; abstr e21042)

-Relationship between neutrophils/lymphocytes and tumor infiltrating lymphocytes stroma in patients with invasive muscle bladder cancer and the response to treatment.
    J Clin Oncol 39, 2021 (suppl 15; abstr e16513)

-First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
    J Clin Oncol 39, 2021 (suppl 15; abstr 9000)

-Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
    J Clin Oncol 39, 2021 (suppl 6; abstr 308)

-Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.
    J Clin Oncol 39, 2021 (suppl 6; abstr 239)


2020 ASCO ANNUAL MEETING


-Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA..
    J Clin Oncol 38: 2020 (suppl; abstr 9501)

-Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
    J Clin Oncol 38, 2020 (suppl 6; abstr 617)


2019 ASCO ANNUAL MEETING


-A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared to pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer.
    J Clin Oncol 37, 2019 (suppl; abstr 3113)

2018 ASCO ANNUAL MEETING


-Lympho-platelets relationship as a prognostic factor for advanced colorectal cancer.
    J Clin Oncol 36, 2018 (suppl; abstr e15667)

2017 ASCO ANNUAL MEETING


-Tumor-infiltrating lymphocytes as a prognostic factor in patients with stage I to III breast cancer.
    J Clin Oncol 35, 2017 (suppl; abstr e12042)

-Analysis of lymphocyte-neutrophil relationship in patients with advanced kidney cancer and the response to one-line treatment with target therapies.

    J Clin Oncol 35, 2017 (suppl; abstr e23034)


ESMO VIRTUAL CONGRESS 2021


-696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


ESMO VIRTUAL CONGRESS 2020


-LBA59 - First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9L
Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


EUROPEAN LUNG CANCER CONGRESS 2021


-98O - First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
    Journal of Thoracic Oncology (2021) 16 (suppl_4): S748-S802.

IASLC 19th World Conference on Lung Cancer TORONTO CANADA
-CheckMate 227: Patient Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC
https://doi.org/10.1016/j.jtho.2018.08.261

XXV CONGRESO ARGENTINO E INTERNACION DE ONCOLOGIA CLINICA 2021


-Impacto de la pandemia por COVID-19 en la consulta, diagnóstico y tratamiento en pacientes oncológicos del Instituto Oncológico de Córdoba.


THE NEW ENGLAND JOURNAL OF MEDICINE 2021


- Nivolumab más cabozantinib versus sunitinib para el carcinoma de células renales avanzado.
 N Engl J Med 2021; 384:829-841 DOI: 10.1056/NEJMoa2026982

THE NEW ENGLAND JOURNAL OF MEDICINE 2019


-Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
N Engl J Med 2019; 381:2020-2031, DOI: 10.1056/NEJMoa1910231

JTO - JOURNAL OF THORACIC ONCOLOGY


-First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
Journal of Thoracic OncologyVol. 16Issue 10SupplementS862Published in issue: October 2021
-Durvalumab in Locally-Advanced NSCLC in LATAM: Real World Data from Patients Included in the Early Access Program
Journal of Thoracic OncologyVol. 16Issue 3SupplementS369Published in issue: March 2021
-First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
Journal of Thoracic OncologyVol. 16Issue 4SupplementS750–S751Published in issue: April 2021
-Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
Journal of Thoracic OncologyVol. 16Issue 1SupplementS2Published in issue: January 2021
-Update of the Analysis of the Status of Lymphocyte Infiltration in Patients with NSCLC
Journal of Thoracic OncologyVol. 14Issue 11SupplementS1180–S1181Published in issue: November 2019
-Update of the Analysis of the Status of Lymphocyte Infiltration in Patients with NSCLC
Journal of Thoracic OncologyVol. 14Issue 10SupplementS962Published in issue: October 2019
-CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC
Journal of Thoracic OncologyVol. 13Issue 10SupplementS332Published in issue: October 2018
-Analysis of Toxicities in Patients with Lung Cancer Compared Other Tumors in Inmune Therapy in Our Institution
Journal of Thoracic OncologyVol. 13Issue 9SupplementS172–S173Published in issue: September 2018
-Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC) in Patients (P) Older Than 70
Journal of Thoracic OncologyVol. 13Issue 9SupplementS174–S175Published in issue: September 2018
-Predictive Factors of Brain Metastases Development in Non-Small Cells Lung Cancer (NSCLC)
Journal of Thoracic OncologyVol. 13Issue 9SupplementS176Published in issue: September 2018
-Relationship Between the Expression of pdl1 and the Tumor Infiltrating Lymphocytes in Patients with Advanced Lung Cancer
Journal of Thoracic OncologyVol. 13Issue 9SupplementS177–S178Published in issue: September 2018
-Analysis of the Status of Lymphocyte Infiltration in Patients Diagnosed with Non–Small Cell Lung Cancer
Journal of Thoracic OncologyVol. 13Issue 9SupplementS168Published in issue: September 2018
-Comparative Study of Chemotherapy Regimens Based on Platinum and Its Different Toxicities in Patients With Advanced NSCLC: Track: Advanced NSCLC
Journal of Thoracic OncologyVol. 11Issue 10SupplementS207Published in issue: October 2016
-Delays in the Diagnosis and Treatment of Lung Cancer: Track: Prevention, Early Detection, Epidemiology and Tobacco Control
Journal of Thoracic OncologyVol. 11Issue 10SupplementS185Published in issue: October 2016
-Relationship Between TILs and Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Advanced NSCLC: Track: Advanced NSCLC
Journal of Thoracic OncologyVol. 11Issue 10SupplementS206Published in issue: October 2016

THE LANCET – Medical Journal


-First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet OncologyVol. 22No. 2p198–211Published: January 18, 2021
-Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
The Lancet OncologyVol. 14No. 13p1307–1316Published: November 8, 2013